CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure

BACKGROUND: Cervical cancer is the tenth diagnosed cancer in the world. Early-stage and locally recurrent disease may be cured with radical surgery or chemo-radiotherapy. However, if disease persists or recurs, options are limited and the prognosis is poor. In addition to chemotherapy, bevacizumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Coquan, Elodie, Brachet, Pierre-Emmanuel, Licaj, Idlir, Leconte, Alexandra, Castera, Marie, Lequesne, Justine, Meriaux, Emeline, Bonnet, Isabelle, Lelaidier, Anais, Clarisse, Bénédicte, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465776/
https://www.ncbi.nlm.nih.gov/pubmed/34563169
http://dx.doi.org/10.1186/s12885-021-08758-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465776/
https://www.ncbi.nlm.nih.gov/pubmed/34563169
http://dx.doi.org/10.1186/s12885-021-08758-9

Ejemplares similares